Trials / Terminated
TerminatedNCT02236546
FDG-PET in Advanced Melanoma
FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.
Detailed description
PRIMARY OBJECTIVES: I. To correlate treatment-induced changes in FDG uptake with changes in tumor size and progression-free survival (PFS) in patients receiving therapy for advanced melanoma. II. To correlate treatment-induced changes in FDG uptake with changes in the activity and/or expression of available molecular biomarkers from patients receiving therapy for advanced melanoma. OUTLINE: Patients undergo FDG-PET/CT up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | [18F]fluorodeoxyglucose | FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition. |
| OTHER | Molecular assays on biopsied tissue | Correlative studies |
| DEVICE | positron emission tomography | Undergo FDG-PET/CT |
| DEVICE | computed tomography | CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images. |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2014-10-01
- Completion
- 2015-11-01
- First posted
- 2014-09-10
- Last updated
- 2017-04-13
- Results posted
- 2017-04-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02236546. Inclusion in this directory is not an endorsement.